Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Coronary Stents News

Home | Index > Health > Heart & Blood > Coronary Stents

TAKE THIS POLL
Does John McCain's military service experience give him a substantial advantage over Barack Obama? (Jul. 3, 2008) Yes, such experience is very important for the U.S. president. No. Don't know.

Opening bell: Building permits climb in May 9 Jul 2008 04:31 GMT
... U.S. stock futures rose Monday after a pullback in oil ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
EMEA: DES Coronary Stentmakers Must Show Drug-Device Compatibility 8 Jul 2008 23:32 GMT
... 16 No. 7 EMEA: DES Coronary Stentmakers Must Show Drug-Device Compatibility Manufacturers of drug-eluting coronary stents (DESs) must provide the results of biocompatibility tests of the bare stent platform conducted to ...
Angiotech Pharmaceuticals Inc. CCR Lowered to 'CC', on Watch Neg on Proposed Recapitalization 8 Jul 2008 18:30 GMT
... "The downgrade reflects the possibility of selective default by the ... other than those related to the TAXUS coronary stent system. The pay-in-kind (PIK) feature on the new ...
New Abbott stent gets FDA approval 8 Jul 2008 16:11 GMT
... Thursday, July 03, 2008 | 4:48 PM Many patients ... more flexible and thinner than older models. Drug-coated stents are thought to work better at keeping ...
The Early Edge: Alcoa, Abbott Laboratories, L-3 Communications, and Merrill Lynch 8 Jul 2008 14:30 GMT
... The Early Edge: Alcoa, Abbott Laboratories, L-3 Communications, and Merrill ... between 25% and 30% of the U.S. drug-coated stent market during the next 12 months an ...

Opening View: Brokerage Bunch Bombards Nvidia on Lowered Earnings Guidance 8 Jul 2008 14:30 GMT
... Opening View: Brokerage Bunch Bombards Nvidia on Lowered Earnings ... between 25% and 30% of the domestic drug-coated stent market over the next year. In fact, ...
Two hospitals get new stent to help treat heart patients: Drug-coated device may result in fewer heart attacks 8 Jul 2008 12:37 GMT
... Two hospitals get new stent to help treat heart ... stent in February -- the first new drug-coated stent to gain approval in five years. The ...
Two hospitals get new stent to help treat heart patients: Drug-coated device may result in fewer heart... 8 Jul 2008 11:59 GMT
... Discuss your viewpoints on this subject with others. Join ... stent in February -- the first new drug-coated stent to gain approval in five years. The ... with any competition, the more of these drug-coated stents that become available, the more potential ...
FDA Approves Fourth Drug-Eluting Coronary Stent 8 Jul 2008 04:25 GMT
... ...
Angiotech Spinning Off Non-Taxus Assets 7 Jul 2008 21:50 GMT
... July 8, 2008 | Vol. 5 No. 132 Angiotech Pharmaceuticals is packaging ... its assets not related to the Taxus coronary stent used in cardiac operations into a new subsidiary, ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

Abbott Labs' Xience V launched in the USA 7 Jul 2008 19:21 GMT
... Abbott Labs' Xience V launched in the USA The US ... care major Abbott Laboratories' Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease, ...
TSX tumbles 200-plus points as oil prices fall sharply; N.Y. turns lower 7 Jul 2008 17:51 GMT
... TSX tumbles 200-plus points as oil prices fall sharply; N.Y. ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
Spectranetics Appoints Exec 7 Jul 2008 17:30 GMT
... a Johnson & Johnson company, including division sales manager and director of marketing for coronary stents. A U.S. Army veteran, Voss has also held management positions with Boston Scientific Corp. ...
TSX declines: falling oil depresses energy stocks, helps send NY higher 7 Jul 2008 16:11 GMT
... A pedestrian walks by an electronic stock board outside a ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
UPDATE 3-Angiotech shifts focus with new company 7 Jul 2008 16:05 GMT
... TORONTO, July 7 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO: ) moved ... the company's business other than its Taxus coronary stent system, on which it has relied too heavily ...
Falling oil prices help send TSX lower, New York markets higher 7 Jul 2008 15:53 GMT
... Falling oil prices help send TSX lower, New York markets ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
TSX flat as energy declines, banks advance; lower oil helps send N.Y. higher 7 Jul 2008 15:53 GMT
... TSX flat as energy declines, banks advance; lower oil helps send ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
Anglotech to form new company, offer notes 7 Jul 2008 15:30 GMT
... TORONTO -- Angiotech Pharmaceuticals Inc. said on Monday that it ... the company's business other than its TAXUS coronary stent system. Areas of specialty for the new company ...
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous Bio-engineered R Stent Has Better Outcomes When Compared to Drug-Eluting Stents 7 Jul 2008 15:27 GMT
... Presented by Federico Piscione, M.D., the study's principal investigator and ... uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up ...
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusN 7 Jul 2008 14:30 GMT
... Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology ... uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up ...

THESE STORIES ARE NOT PUBLISHED BY IPD GROUP, INC. AND THESE LINKS WILL TAKE YOU TO OTHER WEBSITES. SOME OF THESE WEBSITES REQUIRE THEIR OWN REGISTRATION TO READ THEIR STORIES. PLEASE READ THE DISCLAIMER FOR MORE DETAILS. >>>

Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 7 Jul 2008 14:13 GMT
... HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data presented ... uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up ...
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bi 7 Jul 2008 14:12 GMT
... Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology ... uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up ...
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting 7 Jul 2008 14:12 GMT
... HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data presented ... uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up ...
Angiotech spinning off non-Taxus assets; private equity invests up to $300M 7 Jul 2008 13:51 GMT
... Angiotech spinning off non-Taxus assets; private equity invests up ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...
Market outlook moderately bright 7 Jul 2008 13:12 GMT
... Overseas stock markets were generally positive Monday and Wall Street ... its assets not related to the Taxus coronary stent into a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ...